Abstract Body

Background

We previously identified autoantibodies to the CD4 molecule (anti-CD4 AAb) in antiretroviral therapy (ART)-naïve people with HIV (PWH) with CD4 counts <100 cells/µL by luciferase immunoprecipitation systems (LIPS). The influence of delayed ART initiation on these AAb and their impact on CD4 count after ART initiation is unclear.

Methods

In the Strategic Timing of Antiretroviral Treatment (START) trial, ART-naïve PWH with CD4>500 cells/µL were randomized to start ART immediately (immediate arm) or delay until CD4<350 cells/µL or development of AIDS (deferred arm). In a random subset of participants (pts), we measured anti-CD4 AAb at baseline and month 24 (M24) by LIPS, defining seropositivity (AAb+) as >25000 relative light units. We used logistic regression models to assess associations with baseline AAb+ and to compare treatment groups for AAb+ at M24. To assess the effect of AAb+ on CD4 recovery with ART use, we compared the mean change in CD4 count between baseline AAb+ vs AAb- pts within the immediate arm.

Results

Baseline characteristics were similar between arms in the random subset of 1199 pts (600 imm., 599 def.); median age was 36 yrs, median CD4 count was 648 cells/µL. Across all pts at baseline, AAb+ was 41%. AAb+ was independently associated with global region and recent (≤6 months) HIV infection, but not with age, sex, CD4 count, or HIV RNA level (Figure 1). By M24, all pts in the immediate and 33% in the deferred arms had started ART. Among all pts, AAb+ decreased from 41% to 26% in the immediate and from 40% to 31% in the deferred arm (M24 OR (def/imm) 1.91, p<0.001). In pts who were AAb- at baseline, 0.3% (imm) and 4.4% (def) became AAb+ at M24. In the immediate arm, AAb+ decreased from 59% at baseline to 15% at M24 in those with recent HIV infection, versus from 40% to 27% in other pts (p<0.001 for difference). In the immediate arm, there was no difference in CD4 recovery from baseline to M24 between AAb+ and AAb- pts (mean increase of 203 vs 202 cells/µL respectively). 

Conclusions

Among pts randomized to immediate ART initiation, anti-CD4 AAb+ was decreased at M24 compared to deferred ART, but AAb+ at baseline was not associated with the rate of CD4 recovery with ART. With immediate ART, AAb+ reverted to negative more commonly in those with recent HIV infection compared to those with longer duration of untreated HIV. These findings indicate that early ART initiation results in reductions in anti-CD4 AAb+, but their pathogenic role in this population remains uncertain.

Table or Figure